These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17145573)

  • 1. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
    Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
    Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
    Otto-Duessel M; Aguilar M; Nick H; Moats R; Wood JC
    Exp Hematol; 2007 Jul; 35(7):1069-73. PubMed ID: 17588475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
    Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating iron overload: the state of the art.
    Hershko C
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring and treatment of iron overload: state of the art and new approaches.
    Porter JB
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
    [No Abstract]   [Full Text] [Related]  

  • 11. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
    Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
    Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
    Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
    Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
    Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.
    Al-Rousan RM; Manzoor K; Paturi S; Arvapalli RK; Laurino JP; Darnon L; Walker EM; Blough ER
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):117-25. PubMed ID: 21593444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
    Hershko C; Link G; Konijn AM; Huerta M; Rosenmann E; Reinus C
    J Lab Clin Med; 2002 Jan; 139(1):50-8. PubMed ID: 11873245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of iron overload and chelation with deferasirox.
    Choudhry VP; Naithani R
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
    Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
    Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.